These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33545008)

  • 1. Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases.
    Campese N; Palermo G; Del Gamba C; Beatino MF; Galgani A; Belli E; Del Prete E; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Proteomics; 2021 Jan; 18(1):27-48. PubMed ID: 33545008
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases.
    Campese N; Beatino MF; Del Gamba C; Belli E; Giampietri L; Del Prete E; Galgani A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
    Expert Rev Neurother; 2021 Sep; 21(9):949-967. PubMed ID: 34365867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio Aβ1-42:p-Tau: a Possible Diagnostic Tool in Differentiating Dementias.
    De Riva V; Galloni E; Lealini B; Zarantonello G; Disco C; Dionisio LD; Meligrana L; Marcon M; Perini F
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
    Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
    Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease.
    Beatino MF; De Luca C; Campese N; Belli E; Piccarducci R; Giampietri L; Martini C; Perugi G; Siciliano G; Ceravolo R; Vergallo A; Hampel H; Baldacci F
    Expert Rev Mol Diagn; 2022 Apr; 22(4):411-425. PubMed ID: 35443850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of proteomics in biomarker discovery in neurodegenerative diseases.
    Davidsson P; Sjögren M
    Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
    Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population.
    Ye LQ; Li XY; Zhang YB; Cheng HR; Ma Y; Chen DF; Tao QQ; Li HL; Wu ZY
    J Neurol Sci; 2020 May; 412():116756. PubMed ID: 32142967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Leuzy A; Ashton NJ; Mattsson-Carlgren N; Dodich A; Boccardi M; Corre J; Drzezga A; Nordberg A; Ossenkoppele R; Zetterberg H; Blennow K; Frisoni GB; Garibotto V; Hansson O
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2121-2139. PubMed ID: 33674895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Cerebrospinal Fluid Superoxide Dismutase 1 a Biomarker of Tau But Not Amyloid-Induced Neurodegeneration in Alzheimer's Disease?
    McLimans KE; Clark BE; Plagman A; Pappas C; Klinedinst B; Anatharam V; Kanthasamy A; Willette AA
    Antioxid Redox Signal; 2019 Sep; 31(8):572-578. PubMed ID: 31088292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.
    Blennow K; Chen C; Cicognola C; Wildsmith KR; Manser PT; Bohorquez SMS; Zhang Z; Xie B; Peng J; Hansson O; Kvartsberg H; Portelius E; Zetterberg H; Lashley T; Brinkmalm G; Kerchner GA; Weimer RM; Ye K; Höglund K
    Brain; 2020 Feb; 143(2):650-660. PubMed ID: 31834365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.